News
TERN
3.025
+0.50%
0.015
Weekly Report: what happened at TERN last week (0428-0502)?
Weekly Report · 3d ago
TERNS PHARMACEUTICALS REPORTS INDUCEMENT GRANTS TO NEW EMPLOYEES UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 5d ago
Mizuho Securities Reaffirms Their Buy Rating on Terns Pharmaceuticals (TERN)
TipRanks · 04/29 22:16
Viking among notable gainers as Pfizer raises deal prospects
Seeking Alpha · 04/29 19:26
Weekly Report: what happened at TERN last week (0421-0425)?
Weekly Report · 04/28 09:17
Novo Nordisk: Examining Tariff And Pricing Risks
Seeking Alpha · 04/26 12:50
Biotech Alert: Searches spiking for these stocks today
TipRanks · 04/24 19:00
Monday Sector Leaders: Biotechnology, Drugs
NASDAQ · 04/21 16:10
Weekly Report: what happened at TERN last week (0414-0418)?
Weekly Report · 04/21 09:18
SA Asks: What's the best weight-loss drug stock right now?
Seeking Alpha · 04/17 20:11
Terns Pharmaceuticals (TERN) Gets a Buy from Mizuho Securities
TipRanks · 04/15 10:17
Viking, Structure, Metsera on a tear as Pfizer drops obesity pill
Seeking Alpha · 04/14 15:03
Weekly Report: what happened at TERN last week (0407-0411)?
Weekly Report · 04/14 09:16
Terns Pharmaceuticals management to meet with Oppenheimer
TipRanks · 04/08 20:10
Weekly Report: what happened at TERN last week (0331-0404)?
Weekly Report · 04/07 09:16
TERNS PHARMACEUTICALS REPORTS INDUCEMENT GRANT TO NEW EMPLOYEES UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/02 20:05
Insider Purchases Worth US$5.17m See Losses As Terns Pharmaceuticals Market Value Drops To US$255m
Simply Wall St · 03/31 10:24
Weekly Report: what happened at TERN last week (0324-0328)?
Weekly Report · 03/31 09:18
Promising Clinical Trials and Strong Financials Drive Buy Rating for Terns Pharmaceuticals
TipRanks · 03/26 18:25
Oppenheimer Remains a Buy on Terns Pharmaceuticals (TERN)
TipRanks · 03/24 11:55
More
Webull provides a variety of real-time TERN stock news. You can receive the latest news about Terns Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TERN
More
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.